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ABSTRACT 
Introduction 
Regulatory T cells (Tregs) are increasingly being recognized as key immunological 
players in immunosuppression and have been seen to be permissive for certain infections.  
Aim 
This study aimed to elucidate the role that Tregs play in symptomatic infection with 
Mycobacterium tuberculosis (TB), both with and without co-infection with  human 
immunodeficiency virus type 1 (HIV 1) by quantification of these cells at ex vivo. It was 
then attempted to characterise the behaviour of FoxP3 positive cells in culture with 
stimulation. 
Methods 
Peripheral blood mononuclear cells were purified from uninfected controls, patients with 
active TB, patients with HIV infection and patients with HIV infection and active TB. 
The frequencies of Tregs were assessed by flow cytometry at ex vivo and again after four 
days of culture with stimulation with anti-CD3, Purified protein derivative, tetanus toxoid 
and HIV peptide superpools (gag and nef). These frequencies were compared between 
the four groups of patients. The ability of Tregs and effector T cells to proliferate was 
also assessed. Interferon-γ secretion was used as a measure of effector T cell response to 
stimulation.  
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Results 
Frequencies of Tregs were significantly reduced in patients with active TB as compared 
with HIV infected patients and uninfected controls. Co-infected individuals showed a 
broad range of frequencies which were not significantly different from controls. These 
frequencies remained stable in culture with the exception of those individuals infected 
with HIV who showed a decline in the frequency of those cells expressing FoxP3 over 
the period. Cells expressing FoxP3 were not anergic and responded to stimulation. HIV 
specific proteins, in addition, resulted in specific effects on the Tregs with a positive 
interferon response to gag correlating with increased Treg frequencies and FoxP3 
expression in CD4+ T cells correlated with the proliferative response of CD4+ T cells to 
Nef in HIV infected individuals. 
Conclusions 
This study shows significant differences of frequencies of FoxP3 positive producing cells 
in the peripheral blood at ex vivo in patients with active TB. The function of these cells in 
this population is uncertain and further functional data and long-term clinical follow-up is 
required. In addition, the frequencies of these cells remained constant over time and 
showed proliferative response to stimuli (most notably CD3) suggesting that these cells 
may be generated in the periphery.  
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1.0 Introduction: 
1.1 Basic Immunology 
The immune system is the body’s defence against infectious organisms. It is classically 
divided into two distinct systems – the innate immune system and the adaptive immune 
system. The innate immune system, the first line of defence, is non-specific and responds 
to pathogen-associated molecular patterns. Pathogen-associated molecular patterns are 
distinctly foreign molecular signatures which include double-stranded RNA and 
prokaryoytic structural proteins like flagellin amongst others (Gordon 2002, Stenger and 
Modlin 2002). Some of the receptors which detect these foreign signatures are the toll-
like receptors and the complement protein cascade. Cells which are intimately involved 
with the innate response to infection include phagocytes (macrophages, neutrophils and 
dendritic cells) and innate-like lymphocytes (natural killer cells, natural killer T cells and 
B1 B lymphocytes). These cells are responsible for priming the adaptive immune 
response and introducing the foreign organism to the lymphocytes (Bendelac et al 2007, 
Kronenberg and Havran 2007) 
 
Lymphocytes are the key effector cells of the adaptive immune response. Two distinct 
types of lymphocytes are recognized – B cells and T cells. B cells are responsible for the 
humoral or antibody-mediated immune response. Antibodies are small protein molecules 
which are produced to respond to a small signature called an antigen. Once antibodies 
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bind to an antigen, they can trigger a series of processes which include stimulation of 
phagocytosis (opsonisation), stimulation of a cytolytic natural killer cell response 
(antibody dependent cellular cytotoxicity) and activation of the complement cascade 
which in itself results in phagocytosis, recruitment of immune cells to the area and 
cytolysis. 
 
T lymphocytes are the central cell population of the adaptive immune response. T 
lymphocytes are divided into those which express the protein, CD4, on their cell surface 
and those which express the protein, CD8, on the cell surface (Figure 1.1). CD4+ T cells 
are helper T cells – they coordinate the immune response predominantly by the secretion 
of humoral cellular signals called cytokines. CD4+ T cells are classically divided into Th1 
cells which stimulate primarily a cytotoxic response and Th2 cells which secrete 
cytokines which prime a B cell (antibody) response. In addition, regulatory classes of 
CD4+ T cells have been described including Th3 and Tr1 cells which are thought to 
secrete predominantly immunosuppressive cytokines (transforming growth factor β and 
interleukin 10 respectively). CD8+ T cells are cytotoxic T cells – they recognize cells 
with an internal infection through a unique molecule called the Major Histocompatibility 
Class (MHC) I molecule and cause them to undergo apoptosis or kill them through the 
perforin-granzyme pathway. (Lanzavecchia and Sallusto 2001). Recently, a third class of 
effector CD4+ T cells with proinflammatory properties, has been described which 
develop under the influence of the cytokines IL-6 and IL-23 and produce the cytokine IL-
17 which has been implicated in the development of autoimmune disease. 
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The immune system is necessarily under tight regulation in all stages of an immune 
response. The innate immune system, for example, is regulated in its zymogenic 
complement cascade through a number of complement inhibitors which work in an 
analogous way to the anticoagulants in the coagulation cascade. In addition, many of the  
 
 
 
 
 
 
 
 
 
Figure 1.1  
T cell ontogeny and T cell subsets. T cells proliferate in the bone marrow and move to the 
thymus where they undergo a process of conditioning which results in negative selection 
of self reactive T cells.  
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immune system cell populations contain regulatory subsets. For example, natural killer 
cells expressing no or dim CD56 tend to be regulatory rather than cytotoxic (Fan, Yang 
and Wu 2008). It is appropriate, therefore that the cell which coordinates the adaptive 
immune response, the helper T cell, receives tight regulation. 
 
1.2 Characterisation of the Regulatory T cell 
The Regulatory T lymphocyte appears to play a prominent role in regulation of the 
immune system. Although the existence of suppressor cells in the immune system has 
long been postulated, it was only in a recent study by Sakaguchi et al (2000) that a 
method for further characterizing a population of putative regulatory T cells utilizing the 
markers CD4+ (a co-receptor for the T cell receptor utilized in stimulation) and high 
expression of CD25 (the gamma chain of the IL2 receptor), was described. Later, a 
transcriptional factor was identified, the Forkhead Box P3 factor or FoxP3 (a member of 
the winged/helix transcription family) which appears to be central to the activation, 
identification and function of the regulatory T cell (Hori, Nomura and Sakaguchi 2003, 
Ramsdell and Ziegler 2003). This factor was first identified in the Scurfy mouse. The 
Scurfy mouse, analogous to humans with the IPEX syndrome (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome) presents with a disease complex of 
uncontrolled lymphoproliferation, immune paresis and autoimmune phenomena, which is 
generally fatal (Hori, Nomura and Sakaguchi 2003, Hori and Sakaguchi 2004). Some of 
the postulated mechanisms of action of this factor include its direct effects on T cell 
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receptor signalling and its inhibition of other transcription pathways like the nuclear 
factor of activated T cells (NFAT) pathway. 
 
Although FoxP3 has been described as best characterising the Treg population, it has 
limitations. FoxP3 measurement, by flow cytometry or PCR, requires permeabilisation of 
the cell. In addition, studies have suggested that FoxP3 (like CD25) may be upregulated 
as a marker of activation on human T cells as distinct from mice (Morgan et al 2005) 
albeit at lower levels than regulatory T cells and very temporarily (Allan et al 2007). This 
has recently been disputed – the suggestion being that co-culture of FoxP3+ and FoxP3-T 
cells confounds data because the regulatory population is overwhelmed by the FoxP3- 
population and that these cells which are FoxP3+ ex vivo have clear suppressive 
functions (Pillai et al 2008).  Because of the controversy existing regarding the 
characterisation of regulatory T cells in humans, surrogate molecules are currently under 
evaluation including Cytotoxic T lymphocyte associated factor-4 (CTLA-4) and 
Glucocorticoid-induced tumour necrosis factor-like receptor (GITR) amongst others 
(Wing et al 2008, Yong et al 2006). 
 
1.3 Ontogeny of Regulatory T cells 
CD4+ CD25+ thymocytes display full regulatory T cell activity – the thymus hence 
appears to be an important nidus for Treg development (Thompson and Powrie, 2004). In 
addition, neonatal thymectomy is associated with a similar clinical picture to IPEX as a 
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result of Treg deficiency (Chatila 2005). The ability of Tregs to undergo development 
outside the thymus remains controversial (Bachetta et al 2005). 
 
The development of this population appears to be strongly IL2-dependent as evidenced 
by the expression of CD25 and further confirmed by the proliferative response of Tregs 
following the administration of IL2 (Ahmadzadeh and Rosenberg 2006). Tregs have 
previously been described as an anergic population, which are unable to proliferate in the 
absence of the IL-2 (Hori and Sakaguchi, 2004) in vitro. Tregs could thus be a population 
that develops in response to an interaction between the T cell receptor and the MHC II 
antigen expressing self-antigens. Tregs cannot develop in recombination-activating gene 
(RAG) deficient mice (who lack a T-cell receptor) suggesting that the T cell receptor is 
vital for the development of this population of cells. Mice with MHC II expression 
limited to the thymic cortical epithelium (K14-Aβb mice) appear to be able to develop a 
functional Treg population suggesting that MHCII interaction outside of the thymus plays 
no major role in Treg maturation. Other studies have suggested that the thymic medullary 
epithelium may also play a role (Maggi et al 2005). The data support a high-affinity 
TCR-MHC interaction at avidities associated with deletion. Tregs cells appear to be 
subjected to positive selection in the thymus selecting autoreactive cells. They are also 
subject to negative selection as the thymus selects against cells which are strongly 
reactive to self-antigens (Hori and Sakaguchi, 2004, Chatila 2005). TCR variability in the 
population is as marked as in CD4+ CD25- T cells suggesting that the population does not 
represent a recently activated set of lymphocytes (Fujisima et al 2005, Bosco et al 2005) 
An increased strength of the TCR signal is associated with a decreased suppressive 
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activity of Tregs (Baecher-Allan, Wolf and Hafler 2005). Although the role of self-antigens 
is probably paramount, it is certain that Tregs can recognise pathogenic antigens (notably 
L. major, an intracellular protozoan) through their T cell receptors - whether these 
pathogens are merely cross-reacting with similar self-antigens or play a role in Treg 
ontogeny is unclear (Hsieh et al 2004). 
 
Studies in B7 deficient and CD28 deficient mice (NOD mice), which are unable to 
present antigen effectively to T cells because of an absence of co-stimulatory molecules, 
showed a marked numerical decrease in the population of Tregs, which suggested that 
these stimulatory pathways are necessary in the development of this population. These 
mice were prone to the development of diabetes, which was reversed by Treg transfusion 
(Salomon 2000). Nevertheless, the strength of the TCR signal appears to have an inverse 
relationship with the development of the Treg population (Baecher-Allan, Viglietta and 
Hafler 2005). Antibodies targeted at CD28 have strongly upregulated Treg production and 
have shown some promise in the context of animal models of autoimmunity (Beyersdorf 
et al 2005). 
 
TGFβ appears to have a central role in the development of Tregs, which is now only 
beginning to be elucidated. It upregulates the expression of FoxP3 (Fantini et al 2004, Le 
et al 2005) and indirectly recruits the NFκB and MAP kinase signalling pathways and in 
some cases can attenuate the signalling pathways activated by other molecules e.g. 
lipopolysaccharides (LPS). Maintenance of the Treg population, as well as being 
dependent on IL2, requires TGF-β, which appears to maintain the levels of FoxP3 
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peripherally and plays an important role in their development (Fantini et al 2004). Toll-
like Receptor proteins which play a crucial role in the innate system appear to be 
important in the development of Tregs (especially TLR5). Tregs appear to over-express 
some toll-like receptors and the ligation of TLR5 has been shown to increase the 
suppressive activity of the cells (Crellin et al 2005).  
 
Although the Th1 response appears to be the primary target (through the CD4+ T helper 
cell), Tregs also appear to inhibit several other important immune responses. The Th2 
response may be inhibited through a contact-dependent mechanism on peripheral B 
lymphocytes– the Treg may directly inhibit B-cell somatic hypermutation and class-
switch (Lim et al 2005). Studies in mice that overexpress FoxP3 have also suggested that 
the inhibition of the B lymphocytes may also be related to the inability of CD4+ cells 
adequately to direct the antibody response in mice (Kasprowicz et al 2003) 
 
 Tregs appear to affect other antigen-presenting cells such as monocytes/macrophages 
that appear to downregulate their co-stimulatory molecules in response to Tregs and show 
reduced secretion of proinflammatory cytokines (TNF-α and IL-6) in response to 
stimulation with lipopolysaccharide (Taams et al 2005). Tregs also maintain dendritic 
cells in an inactive state in the absence of a large population of activated T cells or large 
amounts of antigenic stimulation (Serra et al 2003). 
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1.4 Function of Regulatory T cells 
 
Regulatory T cells appear to have multiple functions associated both with the suppression 
of the immune response and paradoxically with its activation (in the interaction of Tregs 
with H. pylori and Leishmania major infection, these cells appear to play a role in a 
memory response recruiting cells to the environment – Thompson and Powrie 2004). The 
function of the Treg population could be characterised as a dominant tolerance 
mechanism – self-reactive T cells can become anergic in the thymus owing to the absence 
of a survival signal but Tregs actively destroy this population. (Sakaguchi 2000, Graca et 
al 2005). 
 
1.4.1 Putative cell-contact mediated mechanisms of suppression.  
Stimulation of Tregs in vivo resulted in an increase in granularity and increased binding 
of antibodies against granzyme but not granzyme B (Grossman 2004). Furthermore, 
inhibitors of the perforin pathway (e.g. EGTA and concanamycin A) seem to limit the 
cytotoxic capacity of Tregs (Grossman 2004). This argues that the Tregs utilise a cell-
mediated cytotoxic process similar to that utilised by the Natural Killer Cell population of 
the innate immune system. In addition, it has been shown that Tregs express CD39, an 
ATPase, which neutralises the proinflammatory ATP in local inflammatory responses 
and generates adenosine which inhibits T effector cells through a cAMP mediated 
mechanism. This suppression results in decreased production of IL-2 by effector T cells 
(Bynoe and Viret 2008)  
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The role of CTLA-4 is uncertain. It has been suggested that CTLA-4, which binds 
strongly to B7 molecules (more strongly than CD28), may result in competitive inhibition 
– effector T cells can no longer access the co-stimulatory molecules (Sato et al 2005). 
CTLA-4 also triggers the induction of indoleamine 2,3-dioxygenase which catalyses 
tryptophan conversion into kinurenins, which are immunosuppressive (Maggi et al 2005). 
Recently, knockout studies in mice suggest that CTLA-4 function is integral to the 
function of Tregs but it is uncertain whether this translates to human Treg populations 
(Wing et al 2008). 
 
Tregs also appear to inhibit a Th2 response through a contact-dependent mechanism on 
peripheral B lymphocytes post-activation – this suppression appears to be linked to an 
immunoglobulin class switch (Lim et al 2005). Interestingly, mice with a FoxP3 mutation 
resulting in a gain of function failed to express an adequate immunoglobulin response in 
vivo and showed markedly disrupted splenic architecture yet the function of the isolated 
B cells in vitro appeared to be normal. This was probably related to the inability of the 
CD4+ T cells to secrete the necessary cytokines required for a class switch to IgG or IgE 
(INF-γ and IL4) and a failure to upregulate membrane ligands CD40 and CD69 
((Kasprowicz et al 2003). Tregs also affect other antigen-presenting cells – 
monocytes/macrophages downregulate their co-stimulatory molecules in response to 
Tregs and show reduced secretion of proinflammatory cytokines (TNF-α and IL-6) in 
response to stimulation with LPS (Taams 2004). Tregs also maintain DCs in an inactive 
state in the absence of a large population of CD154+ CD4+ CD25- T cells or large 
amounts of antigenic stimulation (Serra et al 2003).  
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The Glucocorticoid-induced TNF receptor-related protein (GITR) has a controversial role 
in the function of Tregs. Mouse studies suggest that the production of GITR ligand 
(GITR-L) by antigen presenting cells (by superantigen e.g S. aureus ) results in the 
downregulation of the Treg response (Cardona et al 2006). 
 
A final marker, which is constitutively expressed on Tregs, is CD137 (4-1BB) and 
ligation to CD8+ T cells may have a role to play in their suppressive activity. In 4-1BB 
knock-out mice (a mouse model constitutively lacking CD137), however, Treg function 
appears not to be seriously compromised (Maerten et al 2005). 
 
 
1.4.2 Cytokine secretion  
A co-stimulatory pathway may involve secretion of cytokines – especially IL10, which is 
a potent downregulator of the immune response. This cytokine is secreted by other 
regulatory cells, including Th3 cells and Tr1 cells; but whether it plays a role in the 
function of naturally occurring Tregs is uncertain. (Vieira et al 2004). It was noted that 
FoxP3-transduced cells produced more IL10 mRNA but the exact reason remains unclear 
(O’Garra 2005). Furthermore, Tregs appear to dowregulate the secretion of other 
cytokines, particularly IFN-γ and TNF-α (although possibly not in the early stages of the 
suppressive response – Khazaie and Von Boehmer 2006). The downregulation of 
cytokine expression occurs both with and without suppression of proliferation of effector 
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T cells (Kelsen et al 2005). These are known functions of IL-10 further highlighting its 
possible importance in Tregs.  
 
1.5 The role of Tregs in human disease  
A strong Treg response can be beneficial in some human disease and detrimental in 
others. 
 
Regulatory T cells play a fundamental role in the suppression of autoreactive T cells. 
They appear to function both in draining lymph nodes (attempting to prevent the 
activation of autoreactive cells) and in target organs. They migrate to the target organs as 
the disease progresses with eventual acquisition of adhesion markers. The Tregs are 
targeted at specific autoreactive cells – if there is no target effector T cell population 
directed at a specific antigen (like the pancreatic β islet cells) then Tregs have no function 
(Tonkin et al 2008). In the non-obese diabetic (NOD) mouse model of diabetes, for 
example, endocrine but not exocrine disease is halted, suggesting that the initial 
stimulation of the Treg is vital for its eventual function (Bluestone and Tang 2005).  
 
Defects in FoxP3 have been discovered in multiple autoimmune diseases, suggesting that 
a primary pathology in Treg function or absolute number may be playing a role in the 
pathogenesis of the autoimmune disorders listed below. 
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Studies on mouse colitis as a model for inflammatory bowel disease demonstrate 
mutations in the FoxP3 gene which appear to be responsible for poor Treg function and 
decreased numbers of Tregs in the inflamed mucosa (Kelsen et al 2005) 
 
The link between IPEX (the disease caused by congenital absence of the FoxP3 gene) and 
both eczema and food allergies suggests that these allergies may linked to primary Treg 
defects that both these diseases individually may be related to a primary Treg defect. 
Atopic dermatitis has been linked to abnormal T cell function in the presence of a 
superantigen (Thompson et al 2004) and the use of cyclophosphamide to treat contact 
dermatitis resulted in a paradoxical increase in the reaction owing to the effects on the 
Tregs (Ikezawa et al 2005). Mucosal tolerance in mice has been linked to the 
development of a specific set of Tregs for the antigen. (Winkler et al 2006) 
 
Experimental autoimmune encephalomyelitis (EAE) is the mouse model for human 
demyelinating multiple sclerosis (anti-myelin basic protein). Studies in EAE mice have 
suggested that this disease is also related to poor Treg function and therapies targeting 
Treg proliferation rather than purely T cell depletion appear to hold promise for the 
treatment of this disease in humans (Kelsen et al 2005, Duplan et al 2006). These 
therapies include the use of oestrogen which has been shown to have a stimulatory effect 
on FoxP3 and specific TCR peptides. Another novel therapy is LF-15-0195, which also 
causes the Treg population to expand (Duplan et al 2006). Studies have suggested that 
Tregs may not be responsible for the primary remission of the disease but that secondary 
remissions do not occur in mice with EAE and ablated Tregs (Gartner et al 2006).  
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The pathogenesis of Rheumatoid arthritis appears to be linked to the inability of Tregs to 
control the secretion of inflammatory cytokines by CD4+ T cells. Thus, although the 
absolute numbers of Tregs are normal in most subjects, the disease can be markedly 
improved by adding a suppressor against cytokine secretion like TNF-α. Higher numbers 
of Tregs in joint fluid is linked to an improved prognosis in Rheumatoid Arthritis (Chatila 
2005). 
 
Clinical improvement in asthmatics which is associated with treatment with 
glucocorticoids is associated with an increase in IL10 secretion, FoxP3 mRNA levels and 
with the upregulation of secretion of TGF-β (Karagiannidis et al 2004, Till et al 2004) 
 
Some of the disadvantageous effects of Tregs include their propensity to facilitate 
evasion of the immune system. Two primary pathological processes, namely malignancy 
and infection, have been shown to utilise an expanded regulatory T cell population to 
suppress specific cytotoxic responses. In tumours, a strong cell-mediated immune 
response is associated with improved survival and a less aggressive phenotype. It is 
therefore not surprising that many tumours specifically and non-specifically activate 
Tregs as a strategy for immune evasion. Higher levels of Tregs have been found in many 
haemopoietic malignancies. Non-Hodgkin’s Lymphomas appear to secrete chemotactic 
factors for Tregs including CD122 so that there is a markedly elevated population 
throughout the body (approximately 17% Tregs were found in diseased nodes and 7% in 
non-diseased nodes as opposed to the normal 2-5% - Yang et al 2006). Certain T cell 
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leukaemias express a Treg phenotype, which may be linked to a more aggressive course 
although the exact functional significance in these cells remains unknown (Chen et al 
2006). Gastric and oesophageal carcinomas show an increased size of the population of 
Tregs compared with healthy donors; this correlated positively with increased stage of the 
tumours and with the risk of tumour recurrence (Perrone et al 2008). Higher levels of 
FoxP3 mRNA expression correlate with a poorer prognosis in ovarian cancer (Wolf et al 
2005).  Studies in mice have shown that certain tumours e.g. pancreatic adenocarcinoma 
can induce a regulatory phenotype in previously CD25- FoxP3 – CD4+ cells. Any 
immunomodulatory treatment, for example with dendritic cells focused at cancers (as is 
being considered for melanoma), may have to be associated with immunosuppressive 
therapy in order to eliminate pre-existing population of Tregs (Lopez et al 2005). An 
example would be the administration of IL-2 which is associated with massive 
proliferation of the Treg population (Ahmadzadeh and Rosenberg 2006) 
 
 Tregs also limit the response of the immune system to infections. This can result in 
infection persistence but may also prevent a neutralising response with loss of antigen-
maintained memory (Gavin and Rudensky 2003, O’Garra 2005). In Leishmania spp. 
infections, it has been demonstrated that 50% of the involved T cell populations are Tregs 
with failure of the immune response to eradicate the pathogen (Gavin and Rudensky 
2003). Certain pathogens are associated with the induction of immature dendritic cells 
(DCs), which favours the induction of a regulatory T cell population. Plasmodium 
falciparum scavenges CD36, which prevents the maturation of DCs by LPS and studies 
have demonstrated that an expanded regulatory T cell population is associated with faster 
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rates of parasite growth (Good 2005, Walther et al 2005).  Mannosylated 
lipoarabinomannans (immunogenic glycolipids) from Mycobacterium spp. also inhibit 
Treg maturation and the secretion of IL-12. Ebstein-Barr virus (EBV) expressing cells 
which over-express the Notch ligand, Jagged-1, have been shown to induce the 
development of a Treg population  that suppresses function and proliferation of effector 
cells with possible effector function in transplantation (Vigoroux et al 2003). 
 
1.6 Mycobacterium tuberculosis: the immune response 
The estimated prevalence of active infection with Mycobacterium tuberculosis in 2005 
was approximately 14 million infected individuals, of which 3, 77 million cases were 
based in Sub-Saharan Africa with 340 000 new cases in South Africa alone in 2004 
(World Health Organisation). Owing to the link between TB and HIV, the epidemic of 
tuberculosis continues to escalate.  
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In high prevalence settings, like Sub-Saharan Africa, many individuals are infected with 
Mycobacterium tuberculosis, but not all develop active disease. The WHO Global 
tuberculosis control - surveillance, planning, financing report (2005) indicates that 1.7 
billion people are infected with TB worldwide. Latent tuberculosis is defined by a 
positive skin induration to purified protein derivative in the absence of signs or symptoms 
or typical radiological changes (Jasmer et al, 2004). Latent tuberculosis represents a 
treatment dilemma. For this reason it is important to define distinguish active tuberculous 
disease from asymptomatic infection and the correlates of protection. 
 
The host cell for the mycobacterium is the macrophage. In order to survive within the 
phagosome, the bacterium must subvert the host immune system. The organism gains 
access to the macrophage through the complement receptor 3, which prevents 
proinflammatory activation of this cell (Houyen, Nguyen and Pieters 2006). One of the 
key strategies utilized by the bacillus is inhibition of fusion of the phago-lysosome. The 
mycobacterium appears to disrupt the essential signaling sequence which enables fusion 
of the early and late endosome - this includes the secretion of substances which mimic 
host signal transduction molecules, in particular protein kinase G (Walburger et al 2004) 
and inhibition of calcium signaling by inhibition of the production of sphingosine-1 
phosphate (Thompson et al 2005). Mycobacteria also inhibit the expression of proteins 
with the FYVE domain (a specific zinc finger pattern) including early endosome 
autoantigen 1 (EAA-1) and hepatocyte growth-factor regulated tyrosine kinase substrate 
(Gruenberg and Stenmark 2004) – these proteins are permissive of fusion of the phago-
lysosome. Other immunoevasive strategies include resistance against nitric oxide and its 
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toxic intermediaries and prevention of antigen presentation by attenuating the expression 
of HLA class II molecules (Chan and Flynn 2004). 
 
One of the most important cell populations in the control of tuberculosis infection is the 
CD4+ T cell population – it is clear that an intact CD4+ T cell population correlates with a 
better outcome as studies in patients with compromised helper cell populations have 
shown including those with HIV infection (North and Jung 2004, Kaufmann 2005). 
Absent levels of Th1 cytokines (interferon-γ and IL12) are associated with an inability to 
control tuberculosis disease (Flynn et al 1993, Cooper et al 1993, Cooper et al 1997). 
This suggests that the regulatory T cell population may possibly have a pivotal role in 
determining the outcome of the disease process by inhibiting a TB specific CD4+ T cell 
response. Currently, the role of Tregs is uncertain in the pathogenesis of tuberculosis. A 
small pilot study suggested that the numbers of Tregs are increased in active tuberculosis 
disease (Guyot-Revol et al 2006). These preliminary findings were confirmed by further 
studies (Hougardy et al 2007, Roberts et al 2007). These cells may aid the bacterium (in 
addition to the mechanism described above) in immune evasion. Further investigations 
(Chen et al 2007) suggest that regulatory T cells, as defined by their expression of CD4, 
CD25 and FoxP3 are increased in absolute number and frequency in the blood of patients 
with active tuberculosis which compared with uninfected controls and patients with latent 
tuberculosis. The effects of these cells appear to be diverse including secretion of IL-10 
and suppression of tuberculosis specific interferon-γ secretion (Chen et al 2007). It seems 
unclear as to the role of these cells in suppression of infection.  Studies in mice that have 
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had preferential depletion of the FoxP3-expressing CD4+ T cell population showed a log 
reduction in the colony forming units of Mycobacterium tuberculosis (Scott-Browne et al 
2007). In addition, adoptive transfer of FoxP3 expressing CD4+ T cells into mice resulted 
in suppression of a tuberculosis-specific effector CD4+ T cell response (Kursar et al 
2007). 
 
Infection of a patient with HIV and active tuberculosis disease further complicates studies 
of immune regulation in South African populations. It is estimated by the 2005 report by 
UNAIDS that 60% of patients with tuberculosis infection are co-infected with the virus 
(www.unaids.org). HIV infection itself has been associated with multiple effects on the 
Treg population.  Depletion of CD25+ cells from a PBMC population results in massive 
upregulation of IFN-γ secretion by the remaining T cells suggesting that this population, 
even in HIV positive individuals, is directly responsible for suppressing function of HIV 
specific CD4+ and CD8+ T cells(Nixon, Aandahl and Michaelsson  2005).  This may be 
beneficial in downregulating the immune activation which may be partially responsible 
for CD4+ T cell apoptosis and depletion (Oswald-Richter et al 2004, Eggena et al 2005). 
Nevertheless, because this subset expresses the co-receptor CCR5 and the CD4 molecule, 
they are highly susceptible to infection and are also susceptible to the cytotoxic effects in 
vitro (Chase et al 2007, Oswald-Richter et al 2004).  In addition, their effect on HIV 
pathogenesis in vivo remains to be elucidated. 
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2.0 Aim 
2.1 Primary Aim 
The primary aim of this study was to quantify the number of Tregs, expressing CD25 and 
intracellular FoxP3 in patients with active tuberculosis, patients with HIV infection alone 
or patients with HIV infection and active TB and to compare these to healthy controls, in 
order to determine whether this population of cells could be contributing to the 
pathogenesis of HIV infection or tuberculosis disease by suppressing the immune 
response to these infections. 
 
2.2 Secondary aims 
The secondary aims of the study included elucidating the ability of Tregs to proliferate in 
response to both antigen specific and non-specific stimulation in patients with infections 
mentioned above. It has been suggested that only centrally produced regulatory T cells 
express FoxP3 and that these cells are anergic. Adult patients with depletion of CD4 T 
cells would therefore be unable to regenerate their regulatory T cell population. 
This was compared with the ability of CD4+ and CD8+ T cells which did not express 
FoxP3 to secrete interferon gamma (IFN-γ) and to proliferate in response to the same 
stimulation in culture in order to demonstrate a possible regulatory phenotype in co-
culture in the absence of formal depletion studies.   
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The study also aimed to explore the use of additional surface immunophenotypic markers 
of regulatory T cells including CTLA-4 and GITR and to compare them to FoxP3 in 
order to evaluate their utility as possible surrogate markers for this population.  
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3.0 Methods 
3.1 Patient selection 
Patients were sourced from the Johannesburg Hospital, Hillbrow Primary Health Clinic 
and the Alexandra Primary Health Care Clinics. Each patient gave full informed consent 
and the study was approved by the Ethics Committee of the University of the 
Witwatersrand (Ethics number M060313). Up to 60 ml of blood was collected from a 
peripheral vein using the vacutainer system and anticoagulants: acid citrate dextrose 
(ACD) and Ethylenediamine tetra-acetic acid (EDTA) (Table 3.1) 
HIV infected group 
The patients with documented HIV infection (n=10) were sourced from the Hillbrow 
Wellness Clinic and the Johannesburg Hospital (both the anti-retroviral clinic and the 
wards). The diagnosis had been made by the managing physicians using a  Determine 
HIV-1/2 rapid tests (Abbott Laboratories, USA) and confirmed in the majority of patients 
by a fourth generation ELISA (Abbott Laboratories, USA). The patients were 
antiretroviral drug naïve at time of enrolment and were not taking anti-tuberculous 
chemotherapy. They had no obvious clinical symptoms and signs of active tuberculosis. 
A small subpopulation (N=3) had bone marrow trephine biopsies which were negative 
for the presence of TB granulomata.  
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Active tuberculosis group 
The patients with active Mycobacterium tuberculosis infection (n=14) were diagnosed 
microbiologically by the presence of acid-fast bacilli in the sputum. These patients were 
sourced primarily from the Johannesburg Hospital. The patients with HIV co-infection 
(n=9) were anti-retroviral drug naïve at enrolment. The diagnosis of HIV infection was 
made in a similar manner to that described above. No patient had taken more than 2 doses 
of anti- tuberculous chemotherapy at the time of collection of the samples. 
Uninfected  group 
The uninfected controls (n=10) were sourced from clinically well hospital and laboratory 
staff. The samples were tested anonymously after collection for HIV infection using the 
Abbott determine HIV rapid test. No results of the testing were revealed to the 
participants.  
Table 3.1: Demographic characteristics of patient sub- populations 
Patient group Ethnic group (B=black, 
C=coloured, I=Indian, 
W=white) 
Age group (1<20yrs, 
2 =20-29yrs; 3=30-
39yrs; 4=>40yrs) 
Gender (M=male; 
F=female) 
CD4 count 
(x106/l) 
Uninfected 
population 
B 
B 
B 
B 
3 
3 
3 
1 
F 
F 
F 
M 
831 
973 
1503 
671 
 24 
B 
B 
C 
I 
B 
B 
3 
2 
3 
3 
3 
3 
M 
F 
M 
M 
M 
M 
 
1231 
694 
950 
1332 
818 
915 
HIV infected 
population 
B 
B 
B 
B 
B  
B 
B 
B 
B 
B 
3 
2 
4 
2 
3 
3 
3 
3 
2 
2 
F 
F 
F 
F  
M 
F 
M 
F 
F 
F 
523 
223 
118 
432 
40 
169 
712 
191 
219 
452 
Active TB C 4 M 1503 
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population 
B 
B 
B 
B 
2 
1 
4 
3 
M 
F 
F 
F 
743 
859 
494 
801 
HIV infected 
population 
with active TB 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
4 
2 
2 
3 
3 
3 
3 
4 
3 
4 
F 
F 
M 
M 
M 
M 
F 
F 
M 
M 
8 
131 
563 
1 
2 
43 
59 
655 
68 
258 
 
 
 
 26 
3.2 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
Peripheral blood mononuclear cells were isolated by a standard Ficoll-Hypaque technique 
(Amersham Biosciences, UK). The blood was centrifuged at 2200rpm for 15 minutes 
using a Ficoll density gradient. The buffy coat was removed and washed twice with 
HBSS (Hank's Balanced Saline Solution – Gibco, Scotland). The cells were then counted 
using a Guava Viacount (Guava Technologies, California) according to manufacturer’s 
instructions. Those PBMCs which were not stained with CFSE were resuspended in 
RPMI 1640 medium with added GlutaMAX and 25mM HEPES (Gibco, Scotland), 
supplemented with 10% human serum AB (HuAB) (Gemini Bio-Products, USA) and 
0.1% gentamycin (R10) at a concentration of 2 million cells/ml. 
 
3.3 Cell cultures and stimulations 
The PBMCs were cultured for 96 hours in 24 well round-bottom plates using appropriate 
aseptic techniques. Approximately 2 million cells were cultured in every well. The 
culture medium utilized was RPMI 1640 with glutaMAX and 25mM Hepes with 10% 
HuAB.  
Appropriate stimuli were added to each well. The following stimuli were added: 
1. Anti-CD3 (0.1ug/ml) monoclonal antibody – positive control 
2. Tetanus toxoid (2ug/ml) – an antigen to which most South Africans have been 
exposed in the form of vaccination 
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3. Purified protein derivative (0.01ug/ml – Statens Serum Institut) – a construct of 
peptides derived from mycobacterial species 
4. Gag clade C peptide superpool (2ug/ml – NMI Peptides, Netherlands) – peptides 
of 15 amino acids in length derived from the p55 protein 
5. Nef clade C peptide superpool (2ug/ml – NMI Peptides, Netherlands) – peptides 
of 15 amino acids in length derived from the negative regulatory factor of HIV 
clade C virus 
An unstimulated culture was utilized as a negative control. 
A separate culture was established in tubes for intracellular cytokine staining for 
interferon-γ. An hour after the culture was established, 10ug of Brefeldin A was added. 
These samples were incubated with the above-mentioned stimuli and in the culture 
medium overnight at a slight angle at 37oc in 5% CO2. 
 
3.4 Intracellular cytokine staining for interferon-γ 
Intracellular cytokine staining was performed using a protocol adapted from BD 
Bioscience(http://www.bdbiosciences.com/pharmingen/protocols/Intracellular_Cytokine)
The samples were centrifuged in the culture tubes at 1800 rpm for 5 min. EDTA was then 
added to the samples which were then incubated for 15 min in the dark at room 
temperature. Contaminating red blood cells were lysed with appropriate FACS lysing 
solution for 10 minutes and then samples were centrifuged and resuspended. The cells 
were then washed with 2ml of FACS wash buffer. The sample was centrifuged and 0.5ml 
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FACS Perm solution was added. The sample was incubated for a further 10 minutes in 
the dark and then washed with FACS wash buffer. 
The following antibody panel was utilized for staining using concentrations established 
during the project by formal antibody titration: 
1. CD3 PerCP (15ul) – T cell receptor co-signalling chain 
2. CD4 FITC (10ul) – co-receptor for the T cell receptor in T helper cells, acting to 
recruit downstream signalling molecules 
3. CD8 PE (5ul) – co-receptor for the T cell receptor in cytotoxic T cells, acting to 
recruit downstream signalling molecules 
4. IFN-γ APC (5ul) – T helper 1 cytokine associated with a pro-inflammatory response 
 
3.5 Intracellular staining for FoxP3 
The protocol utilized for FoxP3 staining was that recommended by the manufacturer 
(eBiosciences, UK). The samples were stained at 2 time points i.e. after resting overnight 
and at 96 hours. Briefly, samples rested overnight were centrifuged within their tubes. 
Those samples which had been cultured were harvested by gentle pipetting up and down 
and then decanting into standard tubes. The samples were washed with FACS wash 
solution, centrifuged at 1800 rpm for 5 minutes and the supernatant was discarded. 1ml of 
Fix/Perm Solution (eBiosciences, UK) was then added and the sample was vortexed and 
then incubated at 4°C for 30 minutes. Samples were washed with wash buffer and 
 29 
washed a further two times with 2 ml permeabilisation buffer (eBiosciences, UK) with 
centrifugation and discard of supernatant after each wash. 
 
Antibodies were then added in the following panels: 
1. Panel 1 – CD4 FITC and CD3 PerCP(BD Biosciences, USA), FoxP3 PE 
(eBiosciences, UK) and GITR APC (R&D Systems, USA) 
2. Panel 2 – CD4 FITC, CD3 PerCP and CD25 APC(BD Biosciences, USA) and 
FoxP3 PE (eBiosciences, UK)  
3. Panel 3 – CTLA-4 FITC (R&D Systems, USA), CD3 APC, CD4 PerCP (BD 
Biosciences, USA) and FoxP3 PE (eBiosciences, UK) 
The samples were incubated for 30 minutes in the dark at 4oC. 2ml of Permeabilisation 
buffer were then added and the sample centrifuged. This wash step was repeated. The 
sample was then resuspended in 200ul of cell fixative (4% paraformaldehyde in PBS). 
 
3.6 Carboxyfluorescein succinimidyl ester (CFSE) staining 
The samples to be stained for CFSE were harvested. The cells were placed in a 15ml 
Falcon tube and wrapped in foil to avoid light contamination. 2ml of CFSE was added 
and the samples were incubated in the dark for 7 minutes. The reaction was then stopped 
by adding 4ml ice-cold Fetal Bovine Serum (Gibco, Scotland). The samples were then 
washed twice with R10 to remove excess CFSE.  PBMCs to be stained with CFSE were 
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transferred to a 15 ml falcon tube wrapped in foil.  Additional markers were then added 
including FoxP3 PE (eBioscience, UK) and CD3 APC and CD4 PerCP (BD Biosciences, 
USA). 
 
3.7 Acquisition 
Samples stained with CFSE were acquired solely on a multi-colour LSR II (BD 
Biosciences, USA) utilizing FacsDiva acquisition software (BD Biosciences, San Jose). 
The IFN-γ and remaining FoxP3 panels were acquired both on the LSR II and on the 
FacsCalibur which utilizes CellQuest acquisition software (BD Bioscience, San Jose). 
Both the LSR II and the FacsCalibur underwent daily calibration utilising Rainbow 
Calibration Beads and FacsComp beads (BD Biosciences, USA) as advised by the 
manufacturer. Separate samples were analysed as compensation controls utilizing CD8 
FITC, PE, PerCP and APC stained cells which were prepared with the samples. 
Compensation was done digitally utilising the computer programme FlowJo (Tree Star, 
Stanford USA). A Propodium Iodide control was analysed to assess adequacy of cellular 
permeabilisation. Monoclonal antibody controls were utilised to exclude non-specific 
binding of fluorescent antibodies. 
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3.8 Analysis and Gating strategies 
Analysis was accomplished utilizing FlowJo 6.4.2 software. The samples were analysed 
utilizing the negative control to exclude non-specific binding. In the case of the CFSE 
analysis, the Mississippi Gating strategy (developed by Mark Connors, of the NIH 
Immune Regulatory Laboratory) was utilized to exclude the presence of dead cells. 
CD4+T cells were identified initially by separating the lymphocytes on the basis of their 
low intracellular complexity (low side scatter), small size (low forward scatter) and then 
on the basis of their expression initially of CD3 and then CD4. Gates were established on 
the unstimulated and negative (unstained) controls  
 
3.9 Statistical Analysis 
The data were analysed utilizing the following statistical tests on the STATA statistical 
programme (STATACORP 2005. STATA Statistical Software: release 9. College Station: 
STATCORP LP): 
1. Testing of the samples for normality and homoskedasticity (equal variances) 
using a Shapiro-Wilk (Shapiro and Wilk 1965) 
2. A paired t-test for comparison of means 
3. Sidak adjustment for multiple comparisons 
4. Linear regression and pairwise correlation for the variables of interest. 
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4.0 Results  
4.1 Ex vivo Regulatory T cell frequencies 
An immediate ex-vivo analysis was performed on samples from all four patient groups to 
analyse Treg frequencies. Although previous data (Guyot-Revel et al 2005, Chen et al 
2007) has suggested that the frequencies of Tregs are increased in patients with active 
tuberculosis, these data show a reduced frequency ex vivo in patients with confirmed 
tuberculosis disease (p<0.006) compared with uninfected controls.    
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Figure 4.1 
A comparison of Regulatory T cell frequencies ex vivo in the 4 groups with no exogenous 
stimulation (significantly increased in HIV infected individuals p<0.001 ) 
The frequencies of Tregs ex vivo were increased in patients with HIV (p<0.001) 
compared with uninfected controls, in keeping with the previously described 
Control HIV infected TB diseae HIV infected with TB 
FREQUENCY OF FOXP3 POSITIVE CELLS 
Comparison by group at baseline 
P<0.001 
P<0.006 
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immunoevasive strategy of the virus. There was a broad range of Treg frequencies in the 
group infected with HIV with active TB, but the overall frequency was not significantly 
different from the controls (Figures 4.1 and 4.2) 
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Figure 4.2 
Comparison of FoxP3 expression (y axis) against CD25 expression in CD3+ CD4+ T 
lymphocytes ex vivo in uninfected (a), TB disease (b) and HIV infected (c) individuals 
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4.2 Alterations in Treg frequencies after culture 
The samples were cultured for four days in order to assess whether these populations 
were anergic in culture. In addition, if, as has been suggested, FoxP3 merely represents 
an activation marker, it would be likely that the cells expressing FoxP3 would undergo 
apoptosis. There was indeed a significant decline in the frequency of CD4+ T cells 
expressing FoxP3 after 4 days of culture in the HIV-infected individuals suggesting that 
these cells may have undergone apoptosis although no markers of apoptosis were utilised 
to measure this directly. The frequencies with culture remained stable (compared with 
frequencies immediately ex vivo) in all other population groups suggesting that there was 
no significant proliferation or apoptosis in the absence of stimulation. (Figure 4.3) 
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Figure 4.3 
 Frequencies of Tregs after 4 days of culture with no stimulation (no significant change 
was noted in frequency except in the group infected with HIV only) 
Control HIV infected TB disease HIV infected with TB 
FREQUENCY OF FOXP3 POSITIVE CELLS 
Comparison by group at day 4 
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Anti-CD3, which engages the T cell receptor signalling chain, is a potent T cell stimulant. 
In most groups, stimulation with anti-CD3 resulted in a significant proliferative response 
and a significant increase in the frequency of Tregs compared with frequencies ex vivo. 
The exception was the group of patients who were infected HIV and had active TB 
disease who failed to show a proliferative response even to this stimulant. Tetanus 
(against which, many of the South African population have been immunised), which was 
used as a second positive control, failed to produce a significant proliferative response in 
any of the four population groups (Figure 4.4).  
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Figure 4.4 
Comparison of the effect of anti-CD3 stimulation on Treg frequency after 4 days of 
culture (significant differences compared with ex vivo for control population, HIV 
infected population and patients with TB disease p<0.01, p<0.006 and p<0.001 
respectively)  
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Comparison by group on day 4 with anti  stimulation 
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PPD (Staten Serum Institute, Denmark) is a tuberculous protein derivative and was used 
in all 4 groups to try to stimulate an antigen-specific response, particularly in the groups 
with active tuberculosis. There was, however, no significant response in any population 
group. A single HIV positive patient showed a significant response to PPD stimulation at 
day 4 (103% increase between PPD stimulation and no control) although the overall 
effect on the class as a whole was not significant (Figure 4.5).  
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Figure 4.5 
Response to PPD stimulation at day four by Treg frequency in an HIV infected individual 
compared with unstimulated control (12.7% versus 8.18%) 
 
Two HIV peptide pools were utilised for stimulation – a Gag superpool composed of 70 
peptides and a Nef superpool composed of 50 peptides (NMI peptides). Both superpools 
comprised peptides 15 amino acids in length, with an 11 amino acid overlap. Gag 
proteins include the structural proteins of the viral core (capsid, matrix, and nucleocapsid 
proteins). Nef (negative replication factor) protein appears to be important in viral 
replication and immunomodulation (Pennington et al 1997, Noviello et al 2007, Schindler 
et al 2007) although the extent to which the peptide superpool reflects this function is  
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Figure 4.6 
 A comparison of the effect of stimulation with Gag superpool on Treg frequency in the 4 
patient populations after 4 days of culture– Gag stimulation resulted in a significant 
increase in frequency in the HIV infected patients compared with the other patient 
populations (p<0.05)  
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Figure 4.7  
A comparison of the effect of stimulation with Nef superpool on Treg frequency in the 4 
patient populations after 4 days of culture – Nef stimulation appeared to reduce the 
frequency of cells expressing FoxP3 in the uninfected controls but this trend failed to 
reach significance 
Control HIV infected TB disease HIV infected with TB 
FREQUENCY OF FOXP3 POSITIVE CELLS 
Comparison by group at day 4 with Nef  stimulation 
FREQUENCY OF FOXP3 POSITIVE CELLS 
Comparison at Day 4 with Gag stimulation 
Control HIV infected TB disease HIV infected with TB 
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uncertain. Gag stimulation resulted in a significant increase in Tregs in the patients 
infected with HIV alone (p<0.05 - Figure 4.6). A trend was noted in the uninfected 
controls for a decrease in Treg frequencies compared with ex vivo frequencies in response 
to Nef stimulation but this failed to reach significance (Figure 4.7). No trend was noted 
for a positive or a negative change in Treg frequencies in any other population group. 
 
4.3 Correlation of GITR, CTLA-4 and CD25 high expression as                                   
markers of Tregs 
Staining for FoxP3 necessitates permeabilisation of cells (which kills them) – this 
makes it difficult to assess function in FoxP3 positive cells. In addition, additional 
markers which may be associated with suppressive function have been described on 
cells with a regulatory function. For this reason, this study assessed three markers 
which have been associated with Tregs and correlated their expression with FoxP3. 
Bright expression of CD25 has traditionally been used as a surrogate marker in cases 
where the Treg population was needed intact. These data failed to show a significant 
correlation between CD25 and FoxP3 either at ex vivo or after culture in any patient 
population. Two other putative markers were also assessed in this study – CTLA-4 
which is the regulatory ligand for B7 (a costimulatory molecule expressed by 
professional antigen presenting cells) and GITR which is a glucocorticoid induced 
receptor. CTLA-4 blockade has previously been utilised to promote a 
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proinflammatory response (for example in malignancy – Maker et al 2005). Only 
GITR showed a significant correlation with FoxP3 and only in the uninfected control 
group at ex vivo (a trend was noted after 4 days of culture but this failed to reach 
significance). GITR and CD25 expression levels correlated well at baseline and after 
4 days of culture in the uninfected control group, but this was not reproducible in the 
other groups. (Figure 4.8 and Figure 4.9) 
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Figure 4.8 
A comparison of CD25 high staining, CTLA-4 staining and GITR staining in a 
tuberculosis infected individual at ex vivo – the correlation amongst these markers and 
between these markers individually and FoxP3 was unreliable 
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Figure 4. 9 
 Regression of CD25hi (a), CTLA-4 (b) and GITR (c) expression on FoxP3 failed to show 
a statistically significant correlation with FoxP3 for any of the patient groups (p<0.22, 
p<0.91, p<0.26 respectively) 
 
REGRESSION CD25 ON FOXP3 
REGRESSION CTLA-4 ON FOXP3 
REGRESSION GITR ON FOXP3 
(a)  
(b) 
 (c)  
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4.4 CFSE staining  
CFSE is an intracellular dye which binds DNA and is shared among daughter cells in a 
predictable manner allowing for assessment of cell proliferation. It was utilised in this 
study to assess the proliferative response of cells which expressed FoxP3 and CD4 to the 
exogenous stimuli and to assess whether these cells are anergic in culture. As expected, 
the positive control, anti-CD3, stimulated a strong proliferative response in CD4+ T cells 
expressing FoxP3 and CD4+ T cells which did not express FoxP3 after 4 days in most 
patients (Figure 4.10). The exception was the cohort of patients with HIV infection and 
active TB who showed a significant decrease in frequencies of CD4+ T cells and no CD4+ 
T cell proliferation in response to anti-CD3. This was unexpected and suggested that 
strong stimulation in this population group may have resulted either in anergy or in 
apoptosis in this T cell subset. The possibility that this may have been a result of the 
toxicity of the CFSE dye was excluded – there was no reduction in T cell frequency when 
these cells were exposed to the dye in the absence of anti-CD3 stimulation. It was noted, 
however, that the presence of the dye itself resulted in a significant loss of Tregs in both 
the healthy controls and HIV infected individuals.  
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Figure 4.10 
CFSE dye dilution showing significant proliferation of CD3+ CD4+ FoxP3+ cells in 
response to anti-CD3 stimulation 
 
Proliferation of the non-Treg CD4+ T cells was also assessed to see whether there was a 
response to stimuli. IFNγ secretion by CD4+ FoxP3- T cells and CD8+ T cells was also 
measured and compared with proliferation.  
 
As expected, there was a significant proliferative response in CD4 T cells in all 
populations to anti-CD3 stimulation (except in co-infected subjects as discussed above) 
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which correlated well with IFNγ production by both CD4 and CD8 T cells. There was no 
significant difference in proliferative response to other stimuli, although individual 
patients did show responses to PPD and tetanus, which correlated with their ability to 
upregulate production of IFNγ. Gag and Nef produced weak proliferative responses and 
expression of IFNγ with some exceptions in individual patients (Figure 4.12). 
 
 Interestingly, the proportion of FoxP3+ CD4+ CFSElow T cells correlated positively with 
capability of CD4 cells to express IFN-γ and negatively with the ability of CD8 cells to 
express IFN-γ when stimulated with Gag in uninfected individuals (Figure 4.12).  
 
The ability of CD8 T cells to express IFN-γ correlated negatively with the frequency of 
cells expressing FoxP3 in HIV infected individuals in response to anti-CD3 (p<0.03). 
FoxP3 expression in CD4+ T cells correlated with the proliferative response of CD4+ T 
cells to Nef in HIV infected individuals (Figure 4.13). 
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Figure 4.11: 
Interferon- gamma expression at day 1 by CD4+ T cells in an individual with HIV and 
active TB in response to no stimulation, anti-CD3, Gag superpool and Neg superpool 
(CD4+ T cells on the y-axis and IFN-γ on x-axis). A significant response is shown to the 
HIV specific peptides and to anti-CD3 by the non- CD4+ T cells (defined by their 
expression of CD3)  
Unstimulated population Anti-CD3 Stimulation 
Nef Stimulation Gag Stimulation 
IFNγ expression 
IFNγ expression IFN-γ expression 
IFN-γ expression 
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Figure 4.12 
 A regression of change in FoxP3 on change in IFNγ expression in CD4+ T cells in 
uninfected individuals with Gag stimulation showing a significant correlation (p<0.001) 
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Figure 4.13 
 A linear regression of  change in CFSE low on change in FoxP3 in CD4+ T cells in HIV 
infected individuals showing a significant correlation between proliferation and Treg 
frequencies with Nef stimulation after 4 days of culture (p<0.016) 
LINEA  REGRESSION – IFNγ EXPRESSION ON 
FOXP3 EXPRESSION IN CD4+ T CELLS 
LINEAR REGRESSION – CFSE MEASURED CD4+ T 
CELL PROLIFERATION ON FOXP3 IN HIV 
INFECTED INDIVIDUALS  
Change in % CD4+ T cell expressing FoxP3 with Gag Stimulation 
95 % CI 
R^2 = 0.843 Regression coefficient p<0.001 
Ch
ang
e
 in
 %
 C
D
4
+
 T
 cell
 e
xp
ressing
 IFN
g
 w
ith
 G
ag
 
Stim
ulatio
n
 
 
Change in % CD4+ T cell expressing FoxP3 with Nef Stimulation 
95 % CI R^2 = 0.802 Regression coefficient p<0.016 
Ch
ang
e
 in
 %
 C
D
4
+
 C
FSE
 lo
w
 T
 cells
 w
ith
 N
ef
 Stim
ulatio
n
 
 
 46 
5.0 Discussion 
 
5.1 Ex vivo regulatory T cell frequencies are markedly lower in    
patients with tuberculous disease than in normal controls and in 
patients with HIV infection. 
In contrast to recent findings suggesting that elevated Treg frequencies may be 
responsible for the pathogenesis of symptomatic TB infection (Hougardy et al 2007, 
Guyot-Revel et al 2006) , this study showed significantly reduced levels of Tregs as a 
proportion of the CD3+ CD4+ T cells compared with uninfected controls. This may 
suggest that symptomatic infection in the patient population under investigation may be 
related to a failure to suppress an overactive immune response. Since the primary site of 
infection of the tubercle bacillus is the macrophage, it is possible that suppression of the 
immune response by the bacterium is counterproductive to its survival. Although Tregs 
appear to be increased in frequency in HIV infected individuals, this effect is largely 
ablated when these patients develop active TB disease. This ex vivo reduction in 
frequency was maintained with culture in the patients with tuberculosis showing that the 
proportion may be sustained with time. There was attrition in the frequencies of Tregs in 
HIV infected individuals with culture compared with frequencies ex vivo. This effect has 
been previously described although it is uncertain whether this represents effects of HIV 
proteins or susceptibility of these cells to culture. 
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5.2 Regulatory T cells are not anergic in culture 
It has previously been suggested that naturally occurring Tregs are anergic (Hori, 2004) 
and that there is no response to stimulation in this population in the periphery. This is 
important in patients who have lost a high number of CD4+ T cells as is the case in 
advanced HIV infection because it suggests that a functional thymus will be required to 
replenish the population. The stimulated Treg population (generated in the periphery) 
must therefore consist predominantly of IL-10 or TGF-β secreting cells. This study 
showed significantly higher frequencies of CD4+ T cells expressing FoxP3 with anti-CD3 
stimulation. With CFSE dye dilution, it was clear that this represents in part proliferation 
to this stimulus. In addition, there was significant proliferation of CD4+ T cells 
expressing FoxP3 to tetanus in the uninfected control group.  
 
5.3 Neither GITR nor CTLA4 are reliable markers for assessment of  
Tregs  
CTLA-4 (Cytotoxic T-lymphocyte associated protein 4) has been associated with Treg 
populations (Ramsdell and Ziegler 2003, Thompson and Powrie 2004, Salomon et al 
2000). This molecule is postulated to have a suppressive function accomplished by 
binding to the B7 antigens on the antigen-presenting cells, thus ablating the co-
stimulatory pathways for T cell activation. Nevertheless, its function in the Treg 
population still remains controversial as monoclonal antibodies directed against this 
marker do not appear to impact the progression of autoimmune disease in mice (in this 
case NOD mice or non-obese diabetic mice – Salomon et al 2000). In addition, it does not 
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appear to inhibit CD4+ CD25hi T cell suppressive function in humans’ in vivo or in vitro 
culture, even though CTLA-4 polymorphisms have been associated with autoimmune 
disorders in humans. 
 
Glucocorticoid-induced tumour-necrosis factor receptor-related protein or GITR has been 
linked to the regulatory activities of Tregs (Hisaeda et al 2005, Cardona et al 2006). A 
transfer of T cells, which are depleted for GITR, into mice lacking a thymus results in 
more aggressive autoimmunity than if only CD25 depleted T cells are transferred into 
these mice (Uraushihara et al 2003)  
 
In this study, CTLA-4 and GITR were correlated with FoxP3 and CD25high expression. 
Both FoxP3 and CD25 have been used to define the regulatory population in mice and 
humans, but certain authors have suggested that FoxP3 may be upregulated in response to 
activation (Morgan et al 2005). An attempt was made to characterise these 2 markers, 
with established regulatory functions, on the cell populations in this study to attempt to 
establish a regulatory phenotype in the absence of depletion studies. Neither of these 
markers correlated consistently with FoxP3 expression in this study and could thus not be 
considered useful as a surrogate marker of this population. In this study, both molecules 
were assessed by flow cytometric analysis following the manufacturer’s instructions for 
the monoclonal antibody staining.  Because CTLA-4 and FoxP3 were assessed by 
intracellular staining, compensation was suboptimal and the data regarding this marker 
were treated with reserve. It is possible that it would be preferable to assess these 
molecules by quantitative reverse transcriptase PCR. 
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Other molecules are currently being explored as surface markers for Tregs. Tregs express 
the other 2 chains of the IL2 receptor, CD122 (IL2-R beta chain) and CD132 (IL2-R 
gamma chain). In addition they express the intercellular adhesion molecule, LFA3 or 
CD58. Recent studies have also demonstrated that downregulation of the IL-7α chain 
(CD127) may have utility in characterizing this population (Hartigan-O’Connor et al 
2007). 
 
5.4 Tregs can respond to specific stimuli 
In HIV infected individuals, stimulation with an HIV specific peptide resulted in an 
increase in the frequency of FoxP3-expressing cells as a proportion of CD3+ CD4+ T cells. 
This may represent apoptosis in the non-Treg population rather than active proliferation 
of the Gag specific Tregs.  Gag specific proliferation was not significantly different in the 
HIV infected population compared with either unstimulated cells or with uninfected 
individuals. It is also interesting to note that IFN-γ production in CD4 cells in uninfected 
individuals stimulated with Gag correlated strongly with the frequency of cells ex vivo in 
individuals with active TB disease compared with uninfected controls, no similar 
response was noted in response to stimulation with PPD, which contains mycobacterial 
antigens. It must be noted that the concentration of PPD was suboptimal and that at 
higher concentrations, a response might have been noted. 
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5.5 CD4+ T cell proliferation correlates with interferon-gamma 
production in CD4+ T cells 
As expected, there was a significant correlation between CD4+ proliferation and IFNγ 
production by CD4+ T cells in response to all stimuli in uninfected controls. A significant 
correlation was not present in individuals with active TB for any stimulation apart from 
with PPD. The response to HIV specific peptides within HIV infected individuals with 
and without active TB was broadly divergent from patient to patient. This probably 
suggests that there is no clear uniform pattern and that a larger sample size will be needed 
for greater clarification of the response. 
 
5.6 HIV specific peptides exert an immunomodulatory role in Tregs   
with prolonged exposure 
The frequency of CD4+ T cells expressing FoxP3 in uninfected controls correlated 
positively with the response of these cells by IFNγ secretion at day 1 in response to Gag 
stimulation . In conjunction with the response of cells from an HIV infected individual to 
Gag at day 4, this suggests that this peptide may have a function in selecting out CD4+ T 
cells which respond to this HIV peptide. 
 
There was a highly significant correlation between FoxP3 expression after 4 days of 
culture and CD4 T cell proliferation in HIV patients in response to Nef stimulation. There 
was no significant proliferation of FoxP3 positive cells or increase in the proportion of 
cells which expressed FoxP3 in these individuals although it must also be noted that there 
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was a trend for Nef to reduce FoxP3 expression in uninfected controls. These data 
suggest that Nef may not influence FoxP3 expression directly as an immunosuppressive 
strategy although Nef stimulation also resulted in a significant negative correlation 
between IFNγ secretion by CD8+ T cells and the frequency of FoxP3 cells in uninfected 
controls. Some of the previously described immunological effects of Nef expression 
include CD4 molecule down-regulation and impaired thymocyte proliferation in vivo 
(Pennington et al 1997) and MHC class I and II down-regulation (Schindler et al, 2007; 
Noviello et al 2007) which are all associated with an abnormal immunological synapse 
formation. Polymorphisms in the Nef gene have been associated with differential 
progression of HIV infection to AIDS (Walker et al 2007). These results were obtained 
with a Nef peptide pool, rather than a complete Nef protein and it is unclear what effects 
would be obtained with the full protein structure. 
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6.0 Conclusion 
Tregs have been described as a population of cells which regulate the adaptive immune 
response. Clearly, these cells will be of vital importance in diseases which affect the 
immune system as profoundly as HIV and tuberculosis. This study contains preliminary 
work using flow cytometric assays to assess the frequency of these cells in patients 
affected with these two diseases and attempts to answer further questions regarding the 
behaviour of this population in culture and under conditions of stimulation. 
 
The data are subject to some important limitations. A small sample was investigated and 
thus generalization of these results to the patient population as a whole not feasible and 
requires confirmation in a larger study. In addition, controversy exists as to whether 
FoxP3 is the best marker to characterise human regulatory T cells. Certain studies 
(Morgan et al 2005, Allan et al 2007) suggest that effector T cells may upregulate FoxP3 
transiently in response to activation. It is unclear whether the increased frequency of 
FoxP3-expressing cells in HIV-infected patients in this study represent T cells which are 
subject to chronic activation. Depletion studies using CD25hi to isolate regulatory T cells, 
followed by co-culture with CD25lo cells would have been useful to confirm that the cells 
expressing FoxP3 in this study had regulatory properties. The data does, nevertheless, 
support the findings of other groups that the Treg population is upregulated in HIV 
infected individuals. As the data regarding the role of Tregs in tuberculosis are more 
controversial, the meaning of the reduced frequency of FoxP3 expressing cells in this 
population of patients is uncertain. The data do show conclusively, however, that this 
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population is not anergic in vitro and this may indicate that FoxP3 expressing Tregs can 
be induced by specific stimuli in vivo.  
 
Studies of proliferation of antigen-specific T cells and IFNγ production were performed 
to assess the function of FoxP3 expressing cells on other cells in culture – it has been 
suggested that FoxP3 may be an activation marker (Morgan et al 2005). These did not 
show consistent results although some observations including the significant negative 
correlation between FoxP3 expression and IFNγ production by CD8+ T cells in response 
to Nef stimulation suggest that there may have been a direct suppressive function from 
this population. Future studies using co-cultures of Tregs and antigen-specific cells from 
HIV infected individuals and individuals with active tuberculosis may be of value, 
particularly if it can be shown that Tregs can be isolated and cultured. These data 
question whether bright CD25 expression is a good surrogate marker for FoxP3 and it is 
still unclear how these cells would best be separated in a viable state. The data showing 
the correlation of CD4 proliferation after 4 days of culture with stimulation with Nef and 
the frequency of FoxP3 positive cells at this time point is interesting and the role of Nef 
in this population may be worth exploring further.   
 
Future directions include mapping the pathways of the stimulants, use of other techniques 
to demonstrate the upregulation of FoxP3 in the population (in particular, reverse-
transcription PCR) and exploration of other markers of this population. In addition, a 
longitudinal study to assess whether FoxP3 expression correlates with clinical outcome 
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may be of use in individuals with active tuberculosis or HIV infection. It is possible that 
Treg frequency may be an important clinical marker of progression or response to 
therapy but this will still need to be determined. 
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APPENDIX  
Statistical results for experimental data 
 
Table 4.1: 
Treg frequencies following stimulation compared with unstimulated cells at day 4 in all 
four classes (ND= no statistical difference, I=increased compared with control, 
D=decreased compared with controls) 
 
 
 
 
 
 
 
 
 
 
 
Uninfected controls 
TB diseased 
subjects HIV infected subjects 
Co-infected 
subjects 
Anti-CD3 (0.1ug/ml) I (p<0.011) I (p<0.006) I (p<0.001) ND (p<0.148) 
PPD (0.01ug/ml) ND (p<0.138) ND (p<0.154) ND (p<0.123) ND (p<0.194) 
Tetanus toxoid (2 ug/ml) ND (p<0.071) ND (p<0.125) ND (p<0.051) ND (p<0.304) 
Gag superpool (2ug/ml) ND (p< 0.497) ND (p<0.367) I (p<0.05) ND (p<0.406) 
Nef superpool (2ug/ml) ND (p<0.065) ND (p<0.422) ND (p<0.341) ND (p<0.340) 
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Table 4.2 
CFSE measured proliferation of Tregs to stimulation compared with no stimulation on 
day 4 (ND=no statistical difference, I=increased, D=decreased) 
 
 
Uninfected controls 
TB diseased 
subjects 
HIV infected 
subjects 
Co-infected 
subjects 
Anti-CD3 (0.1ug/ml) I (p<0.020) I (p<0.008) I (p<0.002) D(p<0.05) 
PPD (0.01ug/ml) ND (p<0.194) ND (p<0.184) ND (p<0.098) ND (p<0.278) 
Tetanus toxoid (2 ug/ml) ND (p<0.372) ND (p<0.474) ND (p<0.258) ND (p<0.427) 
Gag superpool (2ug/ml) ND (p<0.310) ND (p<0.269) ND (p<0.356) ND (p<0.400) 
Nef superpool (2ug/ml) ND (p<0.215) ND (p<0.269) ND (p<0.404) ND (p<0.384) 
 
Table 4.3 
Comparison of CFSE measured regulatory T cell proliferation in TB, HIV and coinfected 
subjects compared with uninfected controls (ND=no statistical difference, S=suppressed 
with respect to controls, I=increased with respect to controls 
 
 
TB diseased subjects HIV infected subjects Co-infected subjects 
Unstimulated ND (p<0.261) ND (p<0.156) ND (p<0.352) 
Anti-CD3 (0.1ug/ml) ND (p<0.325) ND (p<0.105) S (p<0.012) 
PPD (0.01ug/ml) ND (p<0.283) ND (p<0.234) ND (p<0.366) 
Tetanus toxoid (2 ug/ml) ND (p<0.357) S (p<0.031) ND (p<0.354) 
Gag superpool (2ug/ml) ND (p<0.232) ND (p<0.251) ND (p<0.372) 
Nef superpool (2ug/ml) ND (p<0.358) ND (p<0.430) ND (p<0.256) 
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Table 4.4 
Correlation between CD4+T cell proliferation and gamma interferon expression by 
CD4+T cells 
 
 
Uninfected 
controls 
HIV infected 
subjects 
TB diseased 
subjects 
Coinfected 
subjects 
Anti-CD3 
Correlation 
coefficient=0.767, 
(p<0.047) 
Correlation 
coefficient=0.451, 
(p<0.671) 
Correlation 
coefficient=-0.906, 
p<0.622 
Correlation 
coefficient=-0.108, 
(p<0.9987) 
PPD 
Correlation 
coefficient=0.960, 
(p<0.000) 
Correlation 
coefficient=0.678, 
(p<0.094) 
Correlation 
coefficient=-0.999, 
(p<0.035) 
Correlation 
coefficient=-0.989, 
(p<0.031) 
Tetanus toxoid 
Correlation 
coefficient=0.929, 
(p<0.003) 
Correlation 
coefficient=0.631, 
(p<0.448) 
Correlation 
coefficient=-0.136, 
p<0.999 
Correlation 
coefficient=-0.220, 
(p<0.997) 
Gag 
Correlation 
coefficient=0.892, 
(p<0.042) 
Correlation 
coefficient=0.213, 
(p<0.956) 
Correlation 
coefficient=0.650, 
(p<0.909) 
Correlation 
coefficient=0.621, 
(p<0.761) 
Nef 
Correlation 
coefficient=0.965, 
(p<0.001) 
Correlation 
coefficient=0.405, 
(p<0.746) 
Correlation 
coefficient=0.993, 
(p<0.07) 
Correlation 
coefficient=0.734, 
(p<0.605) 
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Table 4.5 
Proliferation of FoxP3+ CD4+ T cells correlated with interferon γ production by CD8+ T 
cells  
 
 
Uninfected controls HIV infected subjects 
TB infected 
subjects Coinfected subjects 
Anti-CD3 
Correlation 
coefficient=0.544, 
(p<0.342) 
Correlation 
coefficient=-0.854, 
(p<0.030) 
Correlation 
coefficient=-0.970, 
(p<0.365) 
Correlation 
coefficient=-0.982, 
(p<0.094) 
PPD c=-0.178, p<0.956 c=-0.022, p<1.00 c=-0.985, p<0.460 c=-1, p<0.017 
Tetanus c=0.284, p<0.874 c=-0.032, p<1.00 c=-0.414, p<0.980 c=-1, p<0.09 
Gag c=-0.323, p<0.934 c=-0.393, p<0.825 c=0.972, p<0.386 c=-0.906, p<0.623 
Nef c=-0.881, p<0.026 c=-0.484, p<0.700 c=-0.403, p<0.982 c=-0.403, p<0.982 
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Table 4.6 
FoxP3 frequency correlated against CFSE measured proliferation and secretion of 
interferon gamma by CD4+ T cells 
 
 Uninfected controls 
HIV infected 
individuals 
TB infected 
individuals Coinfected individuals 
Anti-CD3 (2ug/ml)     
FoxP3 frequency 
compared with CD4 
proliferation 
Correlation 
coefficient t=0.68, 
(p<0.872) 
Correlation coefficient 
=252, p<0.995 
Correlation 
coefficient=-0.895, 
(p<0.357) 
Correlation coefficient= 
-0.744, p<0.852 
FoxP3 frequency 
compared with Interferon 
secretion 
Correlation 
coefficient =-0.259, 
(p<0.1128) 
Correlation coefficient 
=0.252, (p<0.995) 
Correlation coefficient 
=-0.969, (p<0.404) 
Correlation coefficient=-
0.529, p<0.852 
PPD (0.01ug/ml)     
FoxP3 frequency 
compared with CD4 
proliferation  
Correlation 
coefficient= 0.400, 
(p<0.615) 
Correlation 
coefficient = 0.021, 
(p=1) 
Correlation 
coefficient =-0.972, 
(p<0.387) 
Correlation coefficient 
=-0.760, (p<0.834) 
FoxP3 frequency 
compared with Interferon 
secretion 
Correlation 
coefficient =0.5, 
(p<0.444) 
Correlation 
coefficient=0.021, 
(p=1) 
Correlation 
coefficient =-0.185, 
( p<0.998) 
Correlation 
coefficient=-0.784, 
(p<0.519) 
Tetanus toxoid (2ug/ml)     
FoxP3 frequency 
compared with CD4 
proliferation 
Correlation 
coefficient =0.605, 
(p<0.232) 
Correlation 
coefficient=0.500, 
(p<0.671) 
Correlation 
coefficient=0.757, 
(p<0.838) 
Correlation coefficient 
=0.124, (p<1) 
FoxP3 frequency 
compared with Interferon 
secretion 
Correlation 
coefficient=0.59, 
(p<0.260) 
Correlation 
coefficient =0.149, 
(p<0.984) 
Correlation 
coefficient=0.537, 
(p<0.988) 
Correlation 
coefficient=0.231, 
(p<0.988) 
Gag superpool (2ug/ml)     
 60 
FoxP3 frequency 
compared with CD4 
proliferation 
Correlation 
coefficient=0.576, 
(p<0.298) 
Correlation 
coefficient=-0.256, 
(p<0.947) 
Correlation 
coefficient=0.791, 
(p<0.804) 
Correlation 
coefficient=-0.731, 
(p<0.858) 
FoxP3 frequency 
compared with Interferon 
secretion 
Correlation 
coefficient=0.921, 
(p<0.001) 
Correlation 
coefficient=-0.173, 
(p<0.98) 
Correlation 
coefficient=-0.186, 
(p<0.99) 
Correlation 
coefficient=0.806, 
(p<0.476) 
Nef superpool (2ug/ml)     
FoxP3 frequency 
compared with CD4 
proliferation 
Correlation 
coefficient=0.364, 
(p<0.707) 
Correlation 
coefficient=0.896, 
(p<0.046) 
Correlation 
coefficient=-0.473, 
(p<0.969) 
Correlation 
coefficient=0.863, 
(p<0.709) 
FoxP3 frequency 
compared with Interferon 
secretion 
Correlation 
coefficient=0.421, 
(p<0.594) 
Correlation 
coefficient =-0.274, 
(p<0.910) 
Correlation 
coefficient=-0.981, 
(p<0.329) 
Correlation 
coefficient=-0.151, 
(p<0.997) 
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